STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.